Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.47 |
| ▸ | GABRP | O00591 | 2/20 | 0.47 |
| ▸ | GABRD | O14764 | 2/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.47 |
| ▸ | GABRE | P78334 | 2/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7599288 | 1.00 | KMT2A (0.52) | KMT2AHTTHCAR2GABRPGABRD | |
| SCHEMBL31276895 | 1.00 | KMT2A (0.52) | KMT2AHTTHCAR2GABRPGABRD | |
| SCHEMBL7334778 | 0.87 | KDM4E (0.50) | KMT2AHTTGABRA5POLBKDM4E | |
| SCHEMBL5904298 | 0.84 | HTT (0.52) | KMT2AHTTMAP4K4HDAC1HDAC6 | |
| SCHEMBL487368 | 0.83 | HCAR2 (0.50) | KMT2AHCAR2GABRPGABRDGABRA1 | |
| SCHEMBL30792836 | 0.83 | HCAR2 (0.50) | KMT2AHCAR2GABRPGABRDGABRA1 | |
| SCHEMBL441934 | 0.82 | HTT (0.50) | KMT2AHTTGABRPGABRDGABRA1 | |
| SCHEMBL10386997 | 0.82 | HTT (0.50) | KMT2AHTTGABRPGABRDGABRA1 | |
| SCHEMBL8806697 | 0.81 | HTT (0.48) | KMT2AHTTGABRPGABRDGABRA1 | |
| SCHEMBL31386903 | 0.80 | GABRP (0.52) | KMT2AHCAR2GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119081170-A | Fiber reinforced composite material photovoltaic module frame and preparation method thereof | 江苏东鋆光伏科技有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-119081170-A | Fiber reinforced composite material photovoltaic module frame and preparation method thereof | 江苏东鋆光伏科技有限公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-3887372-B1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2022-10-12 | — | — | EP | disclosed |
| US-20220033396-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2022-02-03 | — | — | US | disclosed |
| EP-3887372-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-06 | — | — | EP | disclosed |
| CN-113166146-A | Other heteroaromatic compounds with anti-RSV activity | 爱尔兰詹森科学公司 | 2021-07-23 | — | — | CN | disclosed |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3724197-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H-PGDS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2020-10-21 | — | — | EP | disclosed |
| CN-111479814-A | Fused pyridines as H-PGDS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2020-07-31 | — | — | CN | disclosed |
| WO-2020109224-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2020-06-04 | — | — | WO | disclosed |
| US-5612334-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5610156-A | USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996022295-A9 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | — | 1996-11-14 | — | — | WO | disclosed |
| WO-1996022293-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022294-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5536718-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-4895950-A | 5-halogeno-6-amino-nicotinic acid halides | BAYER AKTIENGESELLSCHAFT (DE) | 1990-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033396-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | VIM, MAVS, VARS1 | KMT2A 3002/4885HTT 1872/4885HCAR2 3726/4885 |
| US-20210139507-A1 | FUSED PYRIDINES WHICH ACT AS INHIBITORS OF H PGDS | HPGDS, HPGD, PTGS1 | KMT2A 3085/4885HTT 1017/4885HCAR2 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.